Genomatica Enters Into Collaboration With Diversa for Improved Production of Enzyme Products
2006年12月21日 - 10:00PM
PRニュース・ワイアー (英語)
SAN DIEGO, Dec. 21 /PRNewswire/ -- Genomatica, Inc., a leading
biotechnology company forging new paths for the clean sustainable
bio-manufacturing of chemical and biological products from
renewable feedstocks, announced today that it has entered into a
collaboration agreement with Diversa Corporation (NASDAQ:DVSA) to
use Genomatica's proprietary technologies to develop more efficient
bio-manufacturing processes for biologically-derived enzyme
products. Genomatica will strive to attain important productivity
and yield targets to improve manufacturing efficiency and costs.
Under the terms of the multi-year agreement, Genomatica will
receive research support, commercial milestone payments and will be
eligible for royalty payments based on future product sales. "We
are excited to be working with Diversa, a company that has
pioneered the development of bio-derived products for use within a
range of high-value industrial applications," commented Dr.
Christophe Schilling, President and Chief Scientific Officer. "The
marketplace continues to value the growing strengths of our
proprietary Integrated Metabolic Engineering Platform to design and
engineer high performance microbial factories that are optimized to
produce high-value Bio-Products. We look forward to leveraging both
companies' combined expertise in this field to achieve increased
success in the commercialization of Diversa products."
"Manufacturing our enzymes in an efficient manner is a key factor
in the success of our commercialization strategy," stated Edward T.
Shonsey, Chief Executive Officer of Diversa Corporation. "We are
pleased to add Genomatica to our list of collaborators and look
forward to working with them to explore other opportunities of
mutual interest in the future." About Genomatica Genomatica is an
innovative biotechnology company that possesses proprietary
technologies to transform the design, engineering, and manipulation
of living cells for the production of valuable biological and
chemical products. Genomatica is dedicated to developing and
commercializing these high throughput research technologies to
address metabolism-driven product opportunities in the chemical,
material, energy, pharmaceutical, and other industries. As
recognized industry leaders in systems biology with worldwide
commercial partnerships, Genomatica is enabling and accelerating
the development of its customers' bio-derived products and research
programs. By implementing integrated computational/experimental
platforms designed around its advanced award-winning modeling and
simulation technologies, Genomatica performs research for its
customers to rapidly develop next generation product development
processes, and licenses proprietary technologies and intellectual
property for use in its partners own laboratories. Genomatica is
currently pursuing commercial relationships with major industrial
biotechnology, chemical, energy and pharmaceutical companies
seeking to leverage the power of systems biology for rapid
development of biological and chemical products. For more
information, please visit us on our website at
http://www.genomatica.com/. DATASOURCE: Genomatica, Inc. CONTACT:
Christophe H. Schilling, Ph.D., President & Chief Scientific
Officer, or Thomas A. Reed, Vice President, Finance & Corporate
Development, +1-858-824-1771, or Amy L. Buono, Media Relations,
+1-858-824-1771, both of Genomatica, Inc. Web site:
http://www.genomatica.com/
Copyright
Diversa (NASDAQ:DVSA)
過去 株価チャート
から 5 2024 まで 6 2024
Diversa (NASDAQ:DVSA)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Diversa (MM) (ナスダック市場): 0 recent articles
その他のDiversa (MM)ニュース記事